Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.61 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657467 | 1.00 | ADORA3 (0.66) | ADORA3SLC29A1ADORA1P2RX3P2RX2 | |
| SCHEMBL9413321 | 0.91 | SLC29A1 (0.75) | ADORA3SLC29A1ADORA1P2RX3P2RX2 | |
| SCHEMBL9413325 | 0.91 | SLC29A1 (0.75) | ADORA3SLC29A1ADORA1P2RX3P2RX2 | |
| SCHEMBL25698352 | 0.88 | SLC29A1 (0.80) | ADORA3SLC29A1ADORA1ADORA2ALMNA | |
| SCHEMBL20705944 | 0.88 | SLC29A1 (0.80) | ADORA3SLC29A1ADORA1ADORA2ALMNA | |
| SCHEMBL20705924 | 0.87 | P2RX3 (0.72) | SLC29A1ADORA1P2RX3P2RX2 | |
| SCHEMBL25698378 | 0.87 | P2RX3 (0.72) | SLC29A1ADORA1P2RX3P2RX2 | |
| SCHEMBL14344779 | 0.86 | ADORA3 (0.70) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL25698843 | 0.86 | ADORA3 (0.61) | ADORA3SLC29A1ADORA1P2RX3P2RX2 | |
| SCHEMBL8079835 | 0.86 | ADORA3 (0.51) | ADORA3SLC29A1ADORA1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030856-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | claimed |
| US-20030158146-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | US | claimed |
| EP-1030856-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6740644-B2 | ADENOSINE DERIVATIVES, AGONISTS AT THE ADENOSINE A1 RECEPTOR | SMITHKLINE BEECHAM CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20030158146-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | US | disclosed |
| US-6544960-B1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-08 | — | — | US | disclosed |
| EP-1030856-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024451-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158146-A1 | Chemical compounds | CNR1, ADORA3, ADORA1 | ADORA3 2/4885SLC29A1 528/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.